A number of other equities analysts also recently weighed in on ADMA. Oppenheimer set a $14.00 price target on ADMA Biologics and gave the stock a buy rating in a research report on Tuesday, June 25th. Maxim Group reissued a buy rating and set a $12.00 price target on shares of ADMA Biologics in a research report on Tuesday, August 27th. Jefferies Financial Group initiated coverage on ADMA Biologics in a research report on Tuesday, June 4th. They set a buy rating and a $8.00 price target on the stock. Dawson James downgraded ADMA Biologics from a buy rating to a neutral rating and set a $4.00 price target on the stock. in a research report on Monday, August 12th. Finally, HC Wainwright set a $13.00 target price on ADMA Biologics and gave the company a buy rating in a research report on Thursday, May 23rd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $10.17.
NASDAQ ADMA traded down $0.12 during trading on Thursday, reaching $5.10. 753,533 shares of the company’s stock were exchanged, compared to its average volume of 911,375. The business has a 50 day moving average price of $4.00 and a 200-day moving average price of $4.15. The stock has a market capitalization of $309.64 million, a P/E ratio of -3.52 and a beta of 2.66. The company has a debt-to-equity ratio of 1.79, a current ratio of 10.26 and a quick ratio of 7.93. ADMA Biologics has a fifty-two week low of $2.08 and a fifty-two week high of $6.72.
Institutional investors have recently bought and sold shares of the company. Private Advisors LLC acquired a new position in shares of ADMA Biologics in the second quarter valued at approximately $41,000. Parametric Portfolio Associates LLC acquired a new position in shares of ADMA Biologics in the second quarter valued at approximately $49,000. Tower Research Capital LLC TRC grew its position in shares of ADMA Biologics by 13,268.0% in the second quarter. Tower Research Capital LLC TRC now owns 13,368 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 13,268 shares during the last quarter. Citadel Advisors LLC boosted its stake in shares of ADMA Biologics by 96.3% in the second quarter. Citadel Advisors LLC now owns 22,187 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 10,887 shares during the period. Finally, Jane Street Group LLC boosted its stake in shares of ADMA Biologics by 25.1% in the second quarter. Jane Street Group LLC now owns 58,374 shares of the biotechnology company’s stock valued at $226,000 after buying an additional 11,711 shares during the period. 59.07% of the stock is currently owned by institutional investors.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Further Reading: What Factors Can Affect Return on Equity?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.